Cure My Disease

Don't miss your cure!

 Log in / Sign up

Bladder cancer umbrella trial tests immunotherapy combos

NCT ID NCT03869190

Terminated Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 04, 2026 · Updated 3 times

Summary

This study tested several immunotherapy-based drug combinations in 272 people with advanced bladder cancer that had worsened after platinum chemotherapy. The goal was to see which combinations were safest and most effective at shrinking tumors or slowing the disease. Participants received atezolizumab (an immunotherapy) alone or paired with other drugs like enfortumab vedotin, niraparib, or tiragolumab. The flexible 'umbrella' design allowed researchers to add or drop treatment arms based on early results.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Atezolizumab (an immunotherapy drug) combined with other drugs like enfortumab vedotin, niraparib, or tiragolumab
What this could lead to
If successful, this could identify better combination treatments for advanced bladder cancer, potentially improving response rates and delaying disease progression.
What could go wrong
This is an early-phase (1b/2) umbrella study with many different drug combos, so results are preliminary. Some combinations may cause severe side effects or show limited benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infiltrating bladder urothelial carcinoma transitional cell carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER UROTHELIAL CARCINOMA

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, 05505, South Korea

  • Athens Medical Center

    Athens, 151 25, Greece

  • Attiko Hospital University of Athens

    Athens, 12462, Greece

  • Centre Francois Baclesse

    Caen, 14076, France

  • Centre Leon Berard

    Lyon, 69008, France

  • Cleveland Clinic

    Cleveland, Ohio, 44195, United States

  • Clinica Universitaria de Navarra

    Pamplona, Navarre, 31008, Spain

  • Complejo Hospitalario Universitario de Santiago (CHUS)

    Santiago de Compostela, LA Coruna, 15706, Spain

  • Hospital Clinic i Provincial

    Barcelona, 08036, Spain

  • Hospital Clinico Universitario de Valencia

    Valencia, 46010, Spain

  • Hospital General Universitario Gregorio Mara

    Madrid, 28009, Spain

  • Hospital Univ 12 de Octubre

    Madrid, 28041, Spain

  • Hospital Universitario Fundacion Jimenez Diaz.

    Madrid, 28040, Spain

  • Hospital Universitario Reina Sofia

    Córdoba, 14004, Spain

  • Institut Catala d Oncologia Hospitalet

    Barcelona, 08908, Spain

  • Institut Claudius Regaud

    Toulouse, 31052, France

  • Institut régional du Cancer Montpellier

    Montpellier, 34298, France

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, 807, Taiwan

  • Levine Cancer Institute

    Charlotte, North Carolina, 28204, United States

  • MD Anderson Cancer Center

    Madrid, 28033, Spain

  • Memorial Sloan-Kettering Cancer Center

    Commack, New York, 11725, United States

  • Norton Cancer Institute

    Louisville, Kentucky, 40241, United States

  • Royal Marsden NHS Foundation Trust

    Sutton, SM2 5PT, United Kingdom

  • START Madrid. Centro Integral Oncologico Clara Campal

    Madrid, 28050, Spain

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • Severance Hospital

    Seoul, 120-749, South Korea

  • Stanford Cancer Center

    Stanford, California, 94305-5820, United States

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030-4009, United States

  • UCLA Department of Medicine

    Los Angeles, California, 90024, United States

  • UCSF Comprehensive Cancer Ctr

    San Francisco, California, 94115, United States

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio, 44106-1716, United States

  • University of Kentucky Chandler Medical Center

    Lexington, Kentucky, 40536, United States

  • Vall d?Hebron Institute of Oncology (VHIO), Barcelona

    Barcelona, 08035, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.